BBHC
AMRX icon

Brown Brothers Harriman & Co’s Amneal Pharmaceuticals AMRX Stock Holding History

Brown Brothers Harriman & Co’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,688
Closed -$3K – 1260
2022
Q3 		$3K Buy
+1,688
New +$4.73K ﹤0.01% 1360

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Brown Brothers Harriman & Co's AMRX Position: Q4 2022 in Review

Brown Brothers Harriman & Co sold out of Amneal Pharmaceuticals (AMRX) in Q4 2022, closing a stake of 1,688 shares — an estimated $3K sold.

Brown Brothers Harriman & Co first reported a position in AMRX in Q3 2022 and held it in 1 quarter. The position peaked at $3K in Q3 2022. 156 funds tracked by Wall St. Rank hold AMRX as of Q4 2022.

  • Brown Brothers Harriman & Co reported no remaining Amneal Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 1,688 Amneal Pharmaceuticals shares in Q4 2022, an estimated $3K.
  • Brown Brothers Harriman & Co first reported a position in Amneal Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Amneal Pharmaceuticals position peaked at $3K in Q3 2022.
  • 156 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2022.

Based on Brown Brothers Harriman & Co's 13F filing for Q4 2022, filed 9 Feb 2023.